Approved by FDA, Carrimycin Becomes the World's First Synthetic...
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Approved by FDA, Carrimycin Becomes the World's First Synthetic Biological Drug Therapy

By Pharma Tech Outlook | Wednesday, January 06, 2021

Patients take two pills of Carrimycin a day; the drug is kept at room temperature. The length is 14 days for pressing cases and about seven days for mild cases.

FREMONT, CA: Carrimycin has become one of the world’s first synthetic biological drug therapy for extreme COVID-19 to be approved by the US Food and Drug Administration (FDA) for Phase III trials. Testing has also demonstrated that Carrimycin successfully treats patients who have been hospitalized with severe symptoms of COVID-19, allowing them to recover from the worst effects of coronavirus within 14 days.

Laboratory experiments at the beginning of 2020 showed a clear anti-coronavirus effect, inhibiting the replication of 2019-nCoV in cells without causing serious side effects. Phase III trials are based on experiments carried out in China, the findings of which have been accepted by the FDA. “This is a major breakthrough in the treatment of COVID-19, based on international collaboration. The availability of vaccines is, of course, very important. But we know there will always be people who contract COVID, which is why it is so essential we have therapeutic treatments, particularly for anyone hospitalized with a serious case of COVID-19,” said Jiang Enhong, CEO, Tonglian Group.

The FDA-approved international phase III multi-center trial will begin in January 2021 and will run for six months. It will be done in the United States, Argentina, Brazil, Colombia, India, Mexico, Peru, the Philippines, and Ukraine. However, the positions may be changed as the pandemic unfolds. The study would include 300 patients, half of them in the testing group and half of them in the control group.

“What is new is that Carrimycin is anti-viral, combined with the standard antibiotic bacterial treatment, and anti-inflammatory and anti-fibrosis effects. And that is what makes it such a potent treatment against COVID-19. It is a single medicine that avoids the drug interactions of combined treatments with single therapeutic effects,” added Enhong. “We hope Carrimycin will be able to help people all over the world to recover quickly from the worst symptoms of COVID-19. 2020 has been dominated by the impact of the pandemic. In 2021, we’ll be talking about using science to minimize the impact, whether that’s therapeutic treatments, vaccines or restricting infection rates,” he said.

Patients take two pills of Carrimycin a day; the drug is kept at room temperature. The length is 14 days for pressing cases and about seven days for mild cases. Seven-day courses reportedly cost RMB 35000 (USD 5,355).

Weekly Brief

Read Also